Author: admin

Inflammatory Myositis Market Growth Projections 2024-2034: DelveInsight Analysis | CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharma, Pfizer, Horizon Therapeutics, Eli Lilly

The Key Inflammatory Myositis Companies in the market include – CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others.

 

DelveInsight’s “Inflammatory Myositis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Inflammatory Myositis, historical and forecasted epidemiology as well as the Inflammatory Myositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Inflammatory Myositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Myositis Market Forecast

 

Some of the key facts of the Inflammatory Myositis Market Report:

  • The Inflammatory Myositis market size was valued ~USD 589 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In December 2024, argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to enhancing the lives of individuals with severe autoimmune diseases, has announced its decision to advance the development of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study for adults with idiopathic inflammatory myopathies (IIM or myositis). This decision follows an analysis of topline data from the Phase 2 portion of the trial. The ALKIVIA study will continue enrolling patients across three myositis subtypes: immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM).

  • The market size across the 7MM is expected to grow at a CAGR of approximately 11.7%, driven by heightened disease awareness and the introduction of emerging therapies.

  • In 2023, Germany and Italy held the largest market sizes among EU countries, with USD 69 million and USD 47 million, respectively, while Spain had the smallest market size at USD 21 million.

  • Japan had a market size of USD 72 million in 2023, but this is expected to shift in the coming forecast period.

  • In 2023, there were approximately 188 thousand diagnosed cases of inflammatory myositis across the 7MM, with 92 thousand cases estimated to be from the US. These numbers are expected to rise over the forecast period.

  • The diagnosed prevalent cases of inflammatory myositis were classified into specific types: PM, DM, and IBM, with 76 thousand, 84 thousand, and 27 thousand cases respectively across the 7MM in 2023. These numbers are expected to rise by 2034.

  • In 2023, the age-specific cases of inflammatory myositis in the EU4 and the UK were categorized as follows: 3 thousand cases in individuals aged 0–17 years, 12 thousand in those aged 18–44 years, 25 thousand in the 45–64 age group, and 29 thousand cases in individuals aged 65 years and older.

  • In 2023, the diagnosed prevalent cases of inflammatory myositis in Japan were further categorized by gender, with 10 thousand cases in males and 15 thousand cases in females.

  • Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others

  • Key Inflammatory Myositis Therapies: Dazukibart (PF-06823859), Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others

  • The Inflammatory Myositis epidemiology based on gender analyzed that females are more susceptible to suffer from Inflammatory myositis when compared to the male population, in the 7MM

  • The Inflammatory Myositis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Myositis pipeline products will significantly revolutionize the Inflammatory Myositis market dynamics.

 

Inflammatory Myositis Overview

Inflammatory myositis is a group of rare autoimmune disorders characterized by inflammation and weakness of the muscles. These conditions involve inflammation of the muscles (myositis), leading to muscle weakness, pain, and fatigue. There are several types of inflammatory myositis, including polymyositis, dermatomyositis, and inclusion body myositis, each with its own specific features and patterns of muscle involvement.

 

Get a Free sample for the Inflammatory Myositis Market Report:

https://www.delveinsight.com/report-store/inflammatory-myositis-im-market

 

Inflammatory Myositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Inflammatory Myositis Epidemiology Segmentation:

The Inflammatory Myositis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Inflammatory Myositis

  • Prevalent Cases of Inflammatory Myositis by severity

  • Gender-specific Prevalence of Inflammatory Myositis

  • Diagnosed Cases of Episodic and Chronic Inflammatory Myositis

 

Download the report to understand which factors are driving Inflammatory Myositis epidemiology trends @ Inflammatory Myositis Epidemiology Forecast

 

Inflammatory Myositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Myositis market or expected to get launched during the study period. The analysis covers Inflammatory Myositis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Inflammatory Myositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Inflammatory Myositis Therapies and Key Companies

  • Dazukibart (PF-06823859): Pfizer

  • Hizentra: CSL Behring

  • Efgartigimod: Argenx

  • Brepocitinib: Priovant Therapeutics/Roivant

  • Ultomiris: Alexion Pharmaceuticals

  • PF-06823859: Pfizer

  • Daxdilimab: Horizon Therapeutics

  • Baricitinib: Eli Lilly and Company

  • Nipocalimab: Janssen Research & Development

  • PF-06823859: Pfizer

  • Froniglutide: Immunoforge Co. Ltd.

  • Infliximab: Schering-Plough

  • Lovaza: GlaxoSmithKline

  • Rituximab: Roche Pharma AG

 

Discover more about therapies set to grab major Inflammatory Myositis market share @ Inflammatory Myositis Treatment Market

 

Inflammatory Myositis Market Strengths

  • The therapeutic landscape is prolific in determining the efficacy, safety, and tolerability of novel drugs in patients with IM and its various types.

 

Inflammatory Myositis Market Opportunities

  • The rising data on overall Inflammatory Myositis prevalence and its subtypes is expected to add significantly to the patient pool.

 

Scope of the Inflammatory Myositis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others

  • Key Inflammatory Myositis Therapies: Dazukibart (PF-06823859), Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others

  • Inflammatory Myositis Therapeutic Assessment: Inflammatory Myositis current marketed and Inflammatory Myositis emerging therapies

  • Inflammatory Myositis Market Dynamics: Inflammatory Myositis market drivers and Inflammatory Myositis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Inflammatory Myositis Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Myositis Market Access and Reimbursement

 

To know more about Inflammatory Myositis companies working in the treatment market, visit @ Inflammatory Myositis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Inflammatory Myositis Market Report Introduction

2. Executive Summary for Inflammatory Myositis

3. SWOT analysis of Inflammatory Myositis

4. Inflammatory Myositis Patient Share (%) Overview at a Glance

5. Inflammatory Myositis Market Overview at a Glance

6. Inflammatory Myositis Disease Background and Overview

7. Inflammatory Myositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Inflammatory Myositis

9. Inflammatory Myositis Current Treatment and Medical Practices

10. Inflammatory Myositis Unmet Needs

11. Inflammatory Myositis Emerging Therapies

12. Inflammatory Myositis Market Outlook

13. Country-Wise Inflammatory Myositis Market Analysis (2020–2034)

14. Inflammatory Myositis Market Access and Reimbursement of Therapies

15. Inflammatory Myositis Market Drivers

16. Inflammatory Myositis Market Barriers

17. Inflammatory Myositis Appendix

18. Inflammatory Myositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Inflammatory Myositis Market Growth Projections 2024-2034: DelveInsight Analysis | CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharma, Pfizer, Horizon Therapeutics, Eli Lilly

Transdermal Growth Support Solutions Gain Traction as Parents Seek Height Management Before Growth Plate Closure

“Child wearing Hautuki transdermal growth patch”
Growth supplement patches like Hautuki are gaining popularity as parents seek pill-free alternatives. The transdermal market is expected to grow 12% annually over five years.

TDDS-Based Products Appeal to Parents Through Enhanced Convenience and Compliance

As parental interest in children’s height development continues to surge, transdermal patch-based growth support solutions are emerging as a compelling alternative to traditional oral supplements.

Child wearing Hautuki growth Support Pach

Search Volume Surge Reflects Growing Demand

Recent market analysis shows the pediatric growth supplement market expanded 15.2% year-over-year in the first half of 2024. Search terms like “patch-type growth supplements” and “transdermal absorption nutrients” have experienced exponential increases, with leading products such as ‘Hautuki‘ gaining word-of-mouth popularity among parents.

TDDS Technology Highlights Convenience Advantages

Transdermal Drug Delivery System (TDDS)-based patch products offer several distinctive advantages:

  • 24-hour continuous absorption capability
  • Minimized gastrointestinal side effects
  • Reduced risk of missed doses
  • Decreased child resistance to treatment

Industry experts note, “Products like Hautuki and other patch-based solutions are driving continuous market expansion by simultaneously securing convenience and safety.”

Young child measuring height during the critical growth window before growth plate closure.

Medical Experts Emphasize Critical Growth Window

According to pediatric endocrinology experts, a child’s final adult height results from genetic factors (23%) and environmental factors (77%) including nutrition, sleep, and physical activity.

A pediatric endocrinologist from Seoul National University Hospital explained, “The period before growth plate closure, particularly from late elementary through early middle school years, represents the golden window for height development.”

Market Outlook

Health functional food research shows projected 12% average annual growth for the pediatric growth supplement market over the next five years. Industry experts anticipate that comprehensive care products integrating AI-based growth prediction and personalized nutrition will dominate future markets, with leading brands including Hautuki focusing development on these emerging trends.

Media Contact
Company Name: Glovertise
Contact Person: Erick
Email: Send Email
Phone: 01091916367
Address:38, Yeongdong-daero 112-gil #706
City: Gangnam-gu
State: Seoul
Country: Korea
Website: https://glovertise.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Transdermal Growth Support Solutions Gain Traction as Parents Seek Height Management Before Growth Plate Closure

Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech Research

The Key Asthma Companies in the market include – GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Cumberland Pharmaceuticals, Pulmatrix Inc., and others.

 

DelveInsight’s “Asthma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Asthma, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Asthma Market Forecast

 

Some of the key facts of the Asthma Market Report:

  • The asthma market size in the 7MM was around ~USD 19,000 million in 2023, with expectations of growth throughout the forecast period from 2024 to 2034.

  • In May 2025, AstraZeneca’s triple-combination therapy, Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), successfully met the primary endpoints in two Phase III trials for asthma. The KALOS (NCT04609878) and LOGOS (NCT04609904) studies demonstrated that Breztri provided statistically significant and clinically meaningful improvements in lung function compared to dual-combination ICS/LABA therapies. Both trials were randomized, double-blind, and included 4,434 patients with uncontrolled asthma to evaluate Breztri’s potential as an effective treatment option.

  • In May 2025, AstraZeneca’s triple-combination therapy, Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), successfully met the primary endpoints in two Phase III trials for asthma. The KALOS (NCT04609878) and LOGOS (NCT04609904) studies demonstrated that Breztri provided statistically significant and clinically meaningful improvements in lung function compared to dual-combination ICS/LABA therapies. Both trials were randomized, double-blind, and included 4,434 patients with uncontrolled asthma to evaluate Breztri’s potential as an effective treatment option.

  • In February 2025, Enveda, a biotechnology company leveraging AI to transform natural compounds into innovative medicines, is excited to announce the expansion of its lead asset, ENV-294, into a second indication: asthma. Originally developed for atopic dermatitis, this novel therapy offers a groundbreaking approach to treating respiratory inflammatory conditions. To support this progress, Enveda has established an advisory board featuring top experts in asthma research and treatment.

  • In September 2024, Kinaset Therapeutics revealed plans for two oral presentations and a late-breaking poster presentation at the 2024 European Respiratory Society (ERS) Congress. These presentations highlight the potential of Kinaset’s lead clinical candidate, frevecitinib (KN-002), as a treatment for patients with moderate to severe asthma and those with COPD

  • The market size in the 7MM is expected to grow at a compound annual growth rate (CAGR) of approximately 3.9%, driven by rising disease awareness and the introduction of new drugs.

  • In 2023, the UK had the largest market size among EU countries, totaling USD 1.3 million, whereas Spain had the smallest market size at USD 0.4 million.

  • The recent 2024 American Thoracic Society (ATS) conference addressed a wide range of asthma-related topics, from real-world experiences and biomarkers to pediatric asthma and innovative treatments. The conference highlighted significant advancements in asthma research and treatment, including clinical remission indicators and new therapies like inhaled JAK inhibitors and oral STAT6 degraders.

  • The patent protection for the syringe formulation of XOLAIR in the United States and Europe is anticipated to conclude between 2024 and 2025. Currently, there is no presence of generic competition in either the United States or the European Union.

  • CINQAIR possesses biological exclusivity in the United States until 2028 and is granted regulatory exclusivity in Europe until 2026.

  • The collective number of diagnosed prevalent cases of asthma in the 7MM was approximated to be 55 million cases in 2022. Among these cases, the adult population had the highest diagnosed prevalent cases, and this number is anticipated to rise by 2032.

  • As per the World Health Organization (WHO) in 2022, asthma represents a significant non-communicable disease impacting individuals across various age groups, with children being particularly susceptible. It stands as the most prevalent chronic ailment among children. In 2019, approximately 262 million individuals were affected by asthma, resulting in 455,000 deaths.

  • Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others

  • Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others

  • The Asthma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Asthma pipeline products will significantly revolutionize the Asthma market dynamics.

 

Asthma Overview

Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. These symptoms often occur in response to triggers such as allergens, irritants, exercise, or respiratory infections.

 

Get a Free sample for the Asthma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/asthma-market

 

Asthma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Asthma Epidemiology Segmentation:

The Asthma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Asthma

  • Prevalent Cases of Asthma by severity

  • Gender-specific Prevalence of Asthma

  • Diagnosed Cases of Episodic and Chronic Asthma

 

Download the report to understand which factors are driving Asthma epidemiology trends @ Asthma Epidemiology Forecast

 

Asthma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Asthma market or expected to get launched during the study period. The analysis covers Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Asthma Therapies and Key Companies

  • GSK3511294 (Depemokimab): GlaxoSmithKline

  • Masitinib (AB07105): AB Science

  • PT010: AstraZeneca

  • Dexpramipexole Dihydrochloride: Areteia Therapeutics

  • ARS 1: ARS Pharmaceuticals, Inc.

  • MEDI3506 (tozorakimab): AstraZeneca

  • AZD1402 (PRS-060): Pieris Pharma/AstraZeneca

  • Atuliflapon (AZD5718): AstraZeneca

  • Amlitelimab: Sanofi

  • Rilzabrutinib: Sanofi

  • BOXABAN (Ifetroban): Cumberland Pharmaceuticals

  • RG6341 (GDC-6599): Genentech Research/Roche

  • CBP-201: Suzhou Connect Biopharmaceuticals

  • AVTX-002 (Quisovalimab): Avalo Therapeutics

  • MRx-4DP0004: 4D Pharma plc

  • SB010: Sterna Biologicals

 

Discover more about therapies set to grab major Asthma market share @ Asthma Treatment Landscape

 

Asthma Market Strengths

  • Robust pipeline of drugs targeting a variety of different and more effective pathogenic mechanisms in asthma.

 

Asthma Market Opportunities

  • Availability of varied formulation types and convenient dosing schedules for more effective treatment.

 

Scope of the Asthma Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others

  • Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others

  • Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies

  • Asthma Market Dynamics: Asthma market drivers and Asthma market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Asthma Unmet Needs, KOL’s views, Analyst’s views, Asthma Market Access and Reimbursement

 

To know more about Asthma companies working in the treatment market, visit @ Asthma Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Asthma Market Report Introduction

2. Executive Summary for Asthma

3. SWOT analysis of Asthma

4. Asthma Patient Share (%) Overview at a Glance

5. Asthma Market Overview at a Glance

6. Asthma Disease Background and Overview

7. Asthma Epidemiology and Patient Population

8. Country-Specific Patient Population of Asthma

9. Asthma Current Treatment and Medical Practices

10. Asthma Unmet Needs

11. Asthma Emerging Therapies

12. Asthma Market Outlook

13. Country-Wise Asthma Market Analysis (2020–2034)

14. Asthma Market Access and Reimbursement of Therapies

15. Asthma Market Drivers

16. Asthma Market Barriers

17. Asthma Appendix

18. Asthma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech Research

Wisfile Leads the Way in AI File Renaming with a Free, Privacy-First, On-Device Experience

In today’s cluttered digital world, users struggle with chaotic file systems—wasting hours hunting for documents in folder haystacks, battling disorganized mixes of personal and work files, and enduring inefficient manual sorting. Wisfile emerges as the definitive solution: a free, locally run AI tool that transforms file chaos into an instantly accessible, privacy-first system.

Powered by advanced on-device AI, Wisfile directly addresses core frustrations. Its intelligent engine scans imported files (like PDFs or Word documents), recognizes key content locally—no internet required—and enables effortless bulk renaming. Users customize names via templates or personalized rules, while optional AI categorization moves files into designated folders. Crucially, every operation occurs 100% privately; data never leaves the device, and temporary files auto-delete post-processing.

Unlike subscription-based alternatives, Wisfile is completely free, eliminating hidden costs and restrictions on file quantities or processing time. This ensures users retain full ownership of their data, whether handling sensitive business documents or personal photos.

Wisfile redefines efficiency—delivering organized files, ironclad privacy, and reclaimed time. From academic papers and business documents to personal photo collections, Wisfile makes it easy to bring structure to digital clutter—fast, secure, and completely free. Get started today by downloading Wisfile at https://www.wisfile.ai.

About Wisfile

Wisfile is one of the first products of ATOM INFINITE, a trustworthy AI partner dedicated to solving real-world challenges with intelligent, user-centered technology.

Media Contact
Company Name: Wisfile
Contact Person: Sean Young
Email: Send Email
Country: Singapore
Website: https://www.wisfile.ai/

Gizmobite.com Launches with Exclusive Deals on Premium 3D Scanners and Laser Engravers

Gizmobite.com, the authorized retailer for industry-leading brands including 3DMakerpro and Acmerlaser, is proud to offer exclusive deals, unmatched price protection, and dedicated technical support on the latest 3D scanners and laser engravers. As demand for precision 3D scanning and laser engraving grows, Gizmobite ensures customers receive authentic products, competitive pricing, and exceptional service.

The Grand Opening event is live now. Tech enthusiasts can enjoy up to 43% off on cutting-edge gadgets. The best-selling star – Moose 3D Scanner is now providing a $245 discount.

Unbeatable Value with Gizmobite’s Customer-Centric Benefits

1. 15-Day Price Match Guarantee

Shop with confidence-Gizmobite guarantees the best 3D scanner prices on the market. Found a lower 3D scanner for sale elsewhere? Simply submit a claim within 15 days, and Gizmobite will match it—ensuring you never overpay.

2. Fast, Free Shipping on Orders Over $199

Speed matters. That’s why Gizmobite provides free expedited delivery on all qualifying orders, getting your laser engraver for sale or 3D scanner for sale to your doorstep faster than competitors.

3. Expert Technical Support

Unlike typical retailers, Gizmobite assigns dedicated technicians to assist with setup, troubleshooting, and optimization—because seamless operation is just as important as the purchase itself.

Why Industry Professionals Trust Gizmobite

As an official partner of 3DMakerpro, Acmerlaser, and other top brands, Gizmobite guarantees:

1. Genuine products with full 2-year manufacturer warranties

2. Competitive 3D scanner prices for professionals and hobbyists alike

3. Premium laser engravers for sale, backed by reliable customer care

“Our mission is to make advanced 3D scanning and laser engraving accessible without compromising on service or authenticity,” says Calvin Yu, Sales Director at Gizmobite. “With our price protection, fast shipping, and hands-on support, customers can buy with confidence.”

Explore the Future of Digital Fabrication Today

Whether upgrading your workshop or starting a new creative venture, Gizmobite.com delivers top-tier 3D scanners and laser engravers at unbeatable value.

Visit Gizmobite.com to shop now and experience the difference.

Media Contact
Company Name: Gizmobite Limited
Contact Person: Zach Tang
Email: Send Email
Country: Singapore
Website: https://gizmobite.com/

Symbolsink Celebrates a Decade of Excellence in Stainless Steel Sink Manufacturing for North America

Symbolsink, Malaysia’s largest stainless steel sink manufacturer, is celebrating ten years of growth, innovation, and customer trust in the North American market. The family-owned company has established itself as a reliable supplier of high-quality drawn and handmade sinks, with a strong reputation for craftsmanship, service, and technological leadership.

Seizing Opportunities, Driving Steady Growth

The story of Symbolsink begins with a Malaysian family’s tradition and innovation. Leveraging years of experience in managing family businesses and a deep understanding of the kitchen and bathroom industry, the founder keenly identified industry shifts. In 2012, amid anti-dumping investigations on stainless steel sinks from China, Symbolsink established its first factory in Malaysia, with a dedicated focus on manufacturing drawn stainless steel sinks for the North American market.

From a standing start, the company has scaled its annual production capacity to 800,000 units. Its flagship model, the SS-3218S single-bowl sink, remains a top seller, with monthly sales consistently surpassing 15,000 units.

Backed by reliable quality and superior service, Symbolsink quickly gained market recognition, leading to sustained order growth. Symbolsink expanded with a second drawn sink factory in 2016, a third handmade sink factory in 2018, and further increased its handmade sink production capacity in 2022, creating a diversified product portfolio that covers both drawn sinks and handmade sinks, better serving the needs of North American customers.

Leading with Innovation and Quality

Since its inception, the pursuit of premium quality and innovative technology has helped Symbolsink expand and move forward.

Symbolsink is the first factory in Asia to utilize third-generation automated machines for producing drawn stainless steel sinks. These cutting-edge machines represent the latest technological advances in the industry, enabling Symbolsink to produce high-quality sinks with exceptional efficiency.

Symbolsink is also the first stainless steel sink factory to adopt non-through welding. Thanks to the workers’ exquisite craftsmanship, the sinks Symbolsink offers feature premium corner finishing, which gives them a beautiful, high-end look.

Most stainless steel sinks that Symbolsink produces are cUPC certified, fully compliant with North American market standards, and help customers be more competitive in project bidding.

All of Symbolsink’s three stainless steel sink factories are ISO-certified, which offers reliable product quality and standardized production management.

Thanks to its comprehensive production capabilities, standardized management systems, and consistently high output, etc, Symbolsink was the only stainless steel sink factory in Malaysia that passed rigorous on-site inspections by U.S. Customs officials in 2019.

Market Recognition Fuels the Future

A decade of consistent quality and service has earned Symbolsink widespread market trust. Customers not only value the sinks Symbolsink produces—but also the support and reliability behind them. Symbolsink successfully helps customers start or expand their sink business. The founder shared: “There is one customer who started to buy sinks from Symbolsink in 2015, and developed from a small company that sells only 2,000pcs of sinks annually to 30,000pcs now. And because of high customer satisfaction, old customers of Symbolsink continue recommending new customers to order sinks from Symbolsink.”

Looking ahead, the founder stated, “We will continue to focus on the North American market, delivering better products and services through innovation and quality improvement.” As part of this commitment, Symbolsink has already developed several patented products, set to launch soon, reinforcing its position as an industry innovator and trusted manufacturing partner.

About Symbolsink

Symbolsink is Malaysia’s leading stainless steel sink manufacturer, specializing in the North American market. With advanced technology and strict quality standards, the company offers a comprehensive range of drawn sinks, handmade sinks, and custom solutions.

Media Contact
Company Name: Symbolsink
Contact Person: Ketty Wang
Email: Send Email
Country: Malaysia
Website: https://www.symbolsink.com/

Car T Cell Therapy For Multiple Myeloma Market Growth to Accelerate in Forecast Period (2024-2032), DelveInsight Analyzes by DelveInsight | Johnson & Johnson, Gadeta, Bristol-Myers Squibb, Bluebird

The Key Car T Cell Therapy For Multiple Myeloma Companies in the market include- Johnson & Johnson (Janssen), Bristol-Myers Squibb, Bluebird bio, Novartis, Nanjing IASO Biotherapeutics, Gadeta, Allogene Therapeutics, Celyad Oncology, Luminary Therapeutics, Caribou Biosciences, Cellectis SA, bluebird bio, Juno Therapeutics, CRISPR Therapeutics, and others.

 

DelveInsight’s “Car T Cell Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Car T Cell Therapy For Multiple Myeloma, historical and forecasted epidemiology as well as the Car T Cell Therapy For Multiple Myeloma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Car T Cell Therapy For Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Car T Cell Therapy For Multiple Myeloma Market Forecast

 

Some of the key facts of the Car T Cell Therapy For Multiple Myeloma Market Report:

  • In 2022, the CAR-T therapy market size for Multiple Myeloma in the United States was valued at ~USD 400 million and is projected to experience significant growth by 2032.

  • In March 2025, Janssen’s CARVYKTI (ciltacabtagene autoleucel) is an autologous T-cell therapy engineered to specifically target the B-cell maturation antigen (BCMA). This therapy involves modifying a patient’s own T cells using a transgene that produces a chimeric antigen receptor (CAR), allowing the cells to detect and destroy BCMA-expressing cells—typically present in malignant multiple myeloma plasma cells and late-stage B-lineage cells. The CAR in CARVYKTI features two single-domain antibodies that strongly bind to BCMA, boosting T-cell activation, proliferation, and the elimination of these cancerous cells. Currently, in the UK, CAR-T therapies such as CARVYKTI are only accessible through clinical trials. Janssen has decided not to seek approval for cilta-cel through the National Institute for Health and Care Excellence (NICE), meaning it is not available via the NHS at present, although patients may still access it through ongoing trials.

  • In October 2024, Aurigene Oncology, a division of Dr. Reddy’s Laboratories, has received clearance from the Drugs Controller General of India (DCGI) to commence a Phase 2 clinical trial for Ribrecabtagene autoleucel (DRL-1801), its novel autologous CAR-T cell therapy developed for the treatment of multiple myeloma.

  • In 2022, the total incident cases of multiple myeloma across the 7MM exceeded 70,000 and are expected to rise throughout the forecast period.

  • Data indicates that approximately 50% of newly diagnosed multiple myeloma patients are not suitable for transplant, while nearly one-third of those eligible do not undergo the procedure. In 2022, the 7MM recorded about 47,000 transplant-ineligible and 17,000 transplant-eligible frontline multiple myeloma patients.

  • Multiple myeloma occurs more frequently in males than in females, with over half of the diagnosed cases in the United States being male.

  • In the United States, the highest number of multiple myeloma cases is observed in individuals aged 65 and older, accounting for over 70% of cases, followed by those in the 55–64 and 0–54 age groups.

  • Key Car T Cell Therapy For Multiple Myeloma Companies: Johnson & Johnson (Janssen), Bristol-Myers Squibb, Bluebird bio, Novartis, Nanjing IASO Biotherapeutics, Gadeta, Allogene Therapeutics, Celyad Oncology, Luminary Therapeutics, Caribou Biosciences, Cellectis SA, bluebird bio, Juno Therapeutics, CRISPR Therapeutics, and others

  • Key Car T Cell Therapy For Multiple Myeloma Therapies: CARVYKTI (ciltacabtagene autoleucel), ABECMA (idecabtagene vicleucel), CART-ddBCMA, Arcellx

  • PHE885: CAR-T (CAR-GPRC5D), TEG002, ALLO-715 ± Nirogacestat, CYAD-211, LMY-920, CB-011, UCARTCS1A:, bb21217, CC-98633, CTX120, and others

  • The Car T Cell Therapy For Multiple Myeloma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Car T Cell Therapy For Multiple Myeloma pipeline products will significantly revolutionize the Car T Cell Therapy For Multiple Myeloma market dynamics.

 

Car T Cell Therapy For Multiple Myeloma Overview

CAR T cell therapy for multiple myeloma is a type of immunotherapy that involves genetically modifying a patient’s own T cells to recognize and attack cancer cells. In this therapy, T cells are collected from the patient’s blood and then engineered in a laboratory to express chimeric antigen receptors (CARs) on their surface. These CARs are designed to specifically target a protein called BCMA (B-cell maturation antigen), which is commonly found on the surface of multiple myeloma cells.

 

Get a Free sample for the Car T Cell Therapy For Multiple Myeloma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-market

 

Car T Cell Therapy For Multiple Myeloma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Car T Cell Therapy For Multiple Myeloma Epidemiology Segmentation:

The Car T Cell Therapy For Multiple Myeloma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Car T Cell Therapy For Multiple Myeloma

  • Prevalent Cases of Car T Cell Therapy For Multiple Myeloma by severity

  • Gender-specific Prevalence of Car T Cell Therapy For Multiple Myeloma

  • Diagnosed Cases of Episodic and Chronic Car T Cell Therapy For Multiple Myeloma

 

Download the report to understand which factors are driving Car T Cell Therapy For Multiple Myeloma epidemiology trends @ Car T Cell Therapy For Multiple Myeloma Epidemiology Forecast

 

Car T Cell Therapy For Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Car T Cell Therapy For Multiple Myeloma market or expected to get launched during the study period. The analysis covers Car T Cell Therapy For Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Car T Cell Therapy For Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Car T Cell Therapy For Multiple Myeloma Therapies and Key Companies

  • CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson (Janssen)

  • ABECMA (idecabtagene vicleucel): Bristol-Myers Squibb/Bluebird bio

  • CART-ddBCMA: Arcellx

  • PHE885: Novartis

  • CAR-T (CAR-GPRC5D): Nanjing IASO Biotherapeutics

  • TEG002: Gadeta

  • ALLO-715 ± Nirogacestat: Allogene Therapeutics

  • CYAD-211: Celyad Oncology

  • LMY-920: Luminary Therapeutics

  • CB-011: Caribou Biosciences

  • UCARTCS1A: Cellectis SA

  • bb21217: bluebird bio

  • CC-98633: Juno Therapeutics, a Subsidiary of Celgene

  • CTX120: CRISPR Therapeutics

 

Discover more about therapies set to grab major Car T Cell Therapy For Multiple Myeloma market share @ Car T Cell Therapy For Multiple Myeloma Treatment Landscape

 

Car T Cell Therapy For Multiple Myeloma Market Drivers

  • Increasing prevalence of Multiple Myeloma, increase in technological advancement of CAR T-cell manufacturing in myeloma are some of the important factors that are fueling the Car T Cell Therapy For Multiple Myeloma Market.

 

Car T Cell Therapy For Multiple Myeloma Market Barriers

  • However, high cost associated with the treatment, poor persistence of CAR T cells and other factors are creating obstacles in the Car T Cell Therapy For Multiple Myeloma Market growth.

 

Scope of the Car T Cell Therapy For Multiple Myeloma Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Car T Cell Therapy For Multiple Myeloma Companies: Johnson & Johnson (Janssen), Bristol-Myers Squibb, Bluebird bio, Novartis, Nanjing IASO Biotherapeutics, Gadeta, Allogene Therapeutics, Celyad Oncology, Luminary Therapeutics, Caribou Biosciences, Cellectis SA, bluebird bio, Juno Therapeutics, CRISPR Therapeutics, and others

  • Key Car T Cell Therapy For Multiple Myeloma Therapies: CARVYKTI (ciltacabtagene autoleucel), ABECMA (idecabtagene vicleucel), CART-ddBCMA, Arcellx, PHE885: CAR-T (CAR-GPRC5D), TEG002, ALLO-715 ± Nirogacestat, CYAD-211, LMY-920, CB-011, UCARTCS1A:, bb21217, CC-98633, CTX120, and others

  • Car T Cell Therapy For Multiple Myeloma Therapeutic Assessment: Car T Cell Therapy For Multiple Myeloma current marketed and Car T Cell Therapy For Multiple Myeloma emerging therapies

  • Car T Cell Therapy For Multiple Myeloma Market Dynamics: Car T Cell Therapy For Multiple Myeloma market drivers and Car T Cell Therapy For Multiple Myeloma market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Car T Cell Therapy For Multiple Myeloma Unmet Needs, KOL’s views, Analyst’s views, Car T Cell Therapy For Multiple Myeloma Market Access and Reimbursement

 

To know more about Car T Cell Therapy For Multiple Myeloma companies working in the treatment market, visit @ Car T Cell Therapy For Multiple Myeloma Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Car T Cell Therapy For Multiple Myeloma Market Report Introduction

2. Executive Summary for Car T Cell Therapy For Multiple Myeloma

3. SWOT analysis of Car T Cell Therapy For Multiple Myeloma

4. Car T Cell Therapy For Multiple Myeloma Patient Share (%) Overview at a Glance

5. Car T Cell Therapy For Multiple Myeloma Market Overview at a Glance

6. Car T Cell Therapy For Multiple Myeloma Disease Background and Overview

7. Car T Cell Therapy For Multiple Myeloma Epidemiology and Patient Population

8. Country-Specific Patient Population of Car T Cell Therapy For Multiple Myeloma

9. Car T Cell Therapy For Multiple Myeloma Current Treatment and Medical Practices

10. Car T Cell Therapy For Multiple Myeloma Unmet Needs

11. Car T Cell Therapy For Multiple Myeloma Emerging Therapies

12. Car T Cell Therapy For Multiple Myeloma Market Outlook

13. Country-Wise Car T Cell Therapy For Multiple Myeloma Market Analysis (2019–2032)

14. Car T Cell Therapy For Multiple Myeloma Market Access and Reimbursement of Therapies

15. Car T Cell Therapy For Multiple Myeloma Market Drivers

16. Car T Cell Therapy For Multiple Myeloma Market Barriers

17. Car T Cell Therapy For Multiple Myeloma Appendix

18. Car T Cell Therapy For Multiple Myeloma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Car T Cell Therapy For Multiple Myeloma Market Growth to Accelerate in Forecast Period (2024-2032), DelveInsight Analyzes by DelveInsight | Johnson & Johnson, Gadeta, Bristol-Myers Squibb, Bluebird

LiftmyCV Expands Automated AI Job Search to 10 Platforms

LiftmyCV’s AI job search agent now supports Greenhouse, Wellfound and Glassdoor, as the company continues scaling its automation across more than 10 leading job boards and ATS platforms.

London, UK – 7th August, 2025 – LiftmyCV, a fast-growing startup building AI tools for job seekers, has announced a major expansion of its Automated AI Job Search system. With new integrations for Greenhouse, Glassdoor, and Wellfound, the platform now supports full end-to-end application automation across more than 10 leading job boards and ATS systems.

Founded in 2025, LiftmyCV is on a mission to reduce the stress and repetition of modern job hunting by automating the most time-consuming parts – from resume tailoring to application submissions.

“When we built LiftmyCV, our goal was simple: take the manual grunt work out of applying for jobs,” said Dan Zaitsev, founder and CEO. “Most people waste hours applying to roles they’re not a fit for, or get filtered out by bots. Our platform flips that dynamic. It finds better matches, creates stronger applications, and applies on your behalf – while you do other things.”

Traction and growth

Since launching in February 2025, LiftmyCV has processed over 39,000 job applications for more than 3,380 users in tech, design, and digital roles. Most users report saving several hours per week, while others credit the tool with helping them land interviews within days.

With strong early adoption from remote workers, job seekers, and recent grads, the company is now scaling its infrastructure and preparing for international expansion.

What’s new in this release

LiftmyCV’s latest release focuses on deeper automation, more accurate job matching, and better integration with the user workflow. Here’s what’s new:

Expanded platform coverage: LiftmyCV now supports Greenhouse, Wellfound, and Glassdoor, in addition to LinkedIn Jobs, Workable, Lever, Breezy, Recruitee, Ashby, and Monster, bringing the total to over 10 job boards. This makes LiftmyCV one of the most comprehensive automated job application platforms available.

AI Agent Autorun: With the Chrome extension installed, LiftmyCV’s AI agent automatically activates when a supported job listing is opened. It fills in the application, generates a tailored resume, and saves everything to the job tracker, helping users move faster with less effort.

Smarter role matching: The AI compares each job post to the user’s resume and profile, calculates fit, and filters out irrelevant roles. This ensures the agent applies only to jobs that closely match the user’s skills and experience.

Tailored resumes per job: For every application, LiftmyCV generates a new resume tailored to the job at hand. Each resume is optimized for ATS, includes role-specific keywords, and highlights relevant accomplishments, increasing the chance of passing automated screenings.

Non-stop job search: If one job board runs out of relevant openings, the system continues the search automatically on the next available platform. This ensures uninterrupted application flow and maximizes job exposure without manual switching.

Flexible application modes: Users can choose between Autopilot mode, where the AI manages the full process automatically, or Copilot mode, which allows users to review, edit, or skip applications before submission.

The platform also includes real-time tracking, smart apply limits, customizable filters, and a detailed application history.

About LiftmyCV

LiftmyCV is an AI-powered platform helping people apply for jobs faster and more effectively. The product combines resume generation, cover letter personalization, and full application automation across major job boards. Founded in 2025 by Dan Zaitsev, LiftmyCV was built in collaboration with recruiters, engineers, and career coaches to create a more modern, less stressful job search experience.

The company is self-funded and fully remote, with a global user base spanning the US, the UK, and Europe.

Try the Automated AI Job Search now: https://www.liftmycv.com/automated-job-search/

Media Contact
Company Name: VENTURE HEADS LLP
Contact Person: Dan Zaitsev
Email: Send Email
Country: United Kingdom
Website: https://www.liftmycv.com/automated-job-search/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: LiftmyCV Expands Automated AI Job Search to 10 Platforms

With Dementia On The Rise Are There Steps An Aging Population Can Take To Reduce Risk?

According to a study at NYU Langone Health, dementia cases in the U.S. could double over the next 35 years. A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health suggests severe hearing loss significantly increases the likelihood of dementia, especially in those who do not use hearing enhancement devices.

The Center for Disease Control (CDC) estimates that 22 million workers are exposed to potentially damaging noise levels at work every year. One innovative company, AXIL Brands Inc. (NYSE American: AXIL), is rising to meet this unmet need by combining hearing protection with Bluetooth-enabled earbuds and earmuffs that also offer hearing enhancement and situational awareness. AXIL’s founder, Weston Harris, recognized this gap through his family’s hearing aid clinics, where patients often resisted wearing traditional hearing aids. Additionally, many workers disliked standard hearing protection because it hindered communication.

Meanwhile, the NIH suggests a correlation between cardiovascular health and dementia risk. Middle-aged adults may reduce their chances of cognitive decline by managing high blood pressure and cholesterol. These risk factors can be assessed by a primary care physician or through telehealth platforms such as Hims & Hers Health, Inc. (NYSE: HIMS), which offers consultations and prescriptions for managing weight, blood pressure, and cholesterol when deemed appropriate by licensed providers.

While no single solution guarantees prevention, a combination of lifestyle changes, protective technologies, and proactive medical care may help reduce key dementia risk factors. Prevention continues to be the strongest strategy in slowing the rise of dementia among an aging population.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ITMM Consulting LLC to assist in the distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: With Dementia On The Rise Are There Steps An Aging Population Can Take To Reduce Risk?

August 8: The Final of Singer 2025 – Seven Contestants Compete for the “King of Singers” Title

The final of Hunan TV and Mango TV’s Singer 2025 will be broadcast live on August 8 at 19:30 Beijing time. The candidates for the “King of Singers” include Chen Chusheng, Mickey Guyton, Shan Yichun, A-Lin, BENI, Jess Lee, and Grace Kinstler. These seven talented singers will compete in two rounds for the title. Attention is particularly focused on international contestants Mickey Guyton, Grace Kinstler, BENI from Japan, and Jess Lee from Malaysia, as they strive for recognition in China’s music scene.

Competing for the Title of King of Singers

Singer 2025 has garnered global attention and has aired 12 episodes so far. The final, titled “King of Singers,” will feature performances by the seven contestants, who will be judged through live audience votes to determine the winner.

The final consists of two rounds: the first round is a duet ranking competition, and the second round is a solo ranking competition, with each round contributing 50% to the final score. In addition to the existing “live audience voting,” “cloud international audience,” and “everyone watching together” segments, the final will also invite 100 “live international audience” members for voting. The “everyone watching together” group will expand to 20 members, with 20 bloggers from five major online platforms hosting live watch parties, engaging the public in the crowning of the “King.”

(Mickey Guyton)

During the first round of duets, the seven contestants will team up with guest performers to present fresh interpretations of songs. Chen Chusheng will collaborate with Zheng Jun to sing the rock song Bare, while Mickey Guyton will join American singer Loren Allred to perform the challenging song Never Enough. Shan Yichun and Wang Leehom will deliver a gentle rendition of Falling Leaves Return to the Roots, and A-Lin will partner with Peng Jiawei to revitalize Scars, showcasing their strengths. Japanese singer BENI and Liu Xijun will perform Half Moon Serenade in a captivating mix of Japanese and Cantonese. Jess Lee’s clear and emotional voice will combine with Sun Nan’s unique tone for Burn, while Grace Kinstler and Shanti will sing Just Like Fire, showcasing powerful vocals.

In the second round of solo performances, the contestants are ready to present songs of various styles that they have never sung on stage before, aiming for the coveted title.

(BENI)

Four International Singers Poised for Success

On the Singer 2025 stage, international singers Mickey Guyton, BENI, Jess Lee, and Grace Kinstler have all made impressive contributions. As a country music singer, Mickey aims to introduce the innovative charm of country music to Chinese audiences. She actively learns Chinese and plans to incorporate Chinese elements into her future works, promoting cultural exchange between China and the U.S. Grace, known as the “queen of the stage,” has made a strong impression by learning two Chinese songs. Malaysian singer Jess Lee returns to the “Singer” stage after ten years, moving beyond her previous “powerful voice” label to share her life experiences through song. BENI brings the essence of Japanese music, focusing on emotional expression. These artists transcend language and cultural barriers, using their unique musical talents to create a diverse musical feast for the audience.

(Jess Lee)

(Grace Kinstler)

Over nearly four months, the international singers have gained much from this musical journey. Chinese singers share traditional musical elements in their songs, while foreign singers introduce their unique creative styles, discussing different cultural expressions of music and attempting to blend their musical cultures. Outside the show, the international singers have explored China deeply, immersing themselves in traditional culture and experiencing the unique charm of Eastern aesthetics and the warmth of Chinese hospitality.

On August 8 at 19:30 Beijing time, Chen Chusheng, Mickey Guyton, Shan Yichun, A-Lin, BENI, Jess Lee, and Grace Kinstler will deliver their best performances in pursuit of the title of “King of Singers.” Who will become the champion of Singer 2025? Let’s wait and see!

Media Contact
Company Name: Hunan TV
Contact Person: He Yang
Email: Send Email
Country: China
Website: www.hunantv.com